GC-PROM: validation of a patient-reported outcomes measure for Chinese patients with gastric cancer

Xiaojuan Hu¹, Fen Zhao², Hongmei Yu¹, Yanhong Luo¹, Jinchun Liu³* and Yanbo Zhang¹*

Abstract

Background: There is increasing recognition that PROs are important in the estimation of the burden of long-term survival among patients with gastric cancer. The study aimed to develop a disease-specific instrument to assess patient-reported outcomes for Chinese patients with gastric cancer.

Method: Following the FDA’s draft guidance for patient-reported outcome, conceptual framework and item pool were defined based on relevant existing work. A draft scale was formed after revising some items based on feedback from experts and Chinese patients with gastric cancer. The pre-survey and formal survey were conducted in eight different hospitals in Shanxi Province, and two item-selection process based on classical test theory and item response theory. Finally, the patient-reported outcomes measure for Chinese patients with gastric cancer (GC-PROM) was validated in terms of reliability, validity, and feasibility. The minimal clinically important difference was determined by distribution-based method.

Results: The final GC-PROM consisted of 38 items, 13 subdomains, and 4 domains. Reliability was verified by Cronbach’s alpha coefficient for four domains and 13 subdomains respectively. The validity results showed that the multidimensional scale fulfilled expectations. In the formal survey, the completion rate was 96.16%, and the average filling time was less than half an hour. The values of the minimal clinically important difference were 4.14, 3.41, 3.37, and 3.28 in the four domains.

Conclusions: The GC-PROM had good reliability, validity, and feasibility and thus can be considered an effective clinical evaluation instrument for Chinese patients with gastric cancer.

Keywords: Gastric cancer, Patient-reported outcome, Classical test theory, Item response theory, Minimal clinically important difference

Background

Gastric cancer (gastric carcinoma, GC) is a malignant tumor occurring in the epithelial tissue of the stomach. GC accounts for more than 95% of malignant tumors of the stomach [1]. There are approximately 989,000 new patients with GC worldwide each year, but the incidence of the disease varies greatly by region [2]. Although the diagnosis and treatment of GC are developing, the 5-year survival rate for patients with GC is only 20%. In China, GC is a major public health problem [3]. GC causes physical pain to patients, poor mental state, and enormous costs for many families, which reduce the Chinese patients’ quality of life (QoL). So many patients with GC are focusing more on how improving overall QoL [4].

In recent years, patients’ subjective feelings about treatment have been an important part of the improving patients’ QoL [5]. However, earlier methods were unable to measure patients’ self-reported results, such as physician report [6]. Therefore, new patient-generated reports, also known as patient-reported outcomes (PROs), are now used to assess the overall burden of cancer and the effectiveness of interventions. PROs...
involve reports taken directly from patients regarding their health status, functional status, and treatment experience [7]. In medical care for patients with GC, functional effects have usually been separated into three categories: physiological, psychological, and social. It is possible that treatments may also cause physical discomfort to patients, testing the psychological endurance of both patients and their families [8]. Economic effects have sometimes also been discussed in the functional effects of illness [9]. To select the best therapeutic schedule, it is necessary to carry out a comprehensive assessment of various plans.

At present, the main disease-specific instruments of GC that have been developed are the EORTC quality of life questionnaire-stomach cancer (EORTC QLQ-STO52) [10], the Functional Assessment of Cancer Therapy-gastric (FACT-Ga) [11], quality of life instruments for cancer patients-stomach cancer (QLICP-ST) [12], and the Special Symptom Scale developed by Chen-wun in Taiwan, China [13]. EORTC QLQ-STO 52, FACT-Ga, and QLICP-ST was developed by combining general module with special module. The Chinese version of EORTC QLQ-STO52 and FACT-Ga had been culturally debugged and evaluated [14]. But there were still some items that might not suitable for Chinese culture. QLICP-ST was a gastric cancer scale developed for Chinese cancer patients. However, the disease-specific items might be less than those in the EORTC QLQ-STO52. It had few specific items on the effectiveness, compliance, satisfaction, and side effects in the field of cancer treatment [15]. The Special Symptom Scale developed by Chen-wun also didn’t divide domains [13].

In sum, there are already many reliable scales for measuring the QoL of patients with GC worldwide. However, if used alone, these scales are often not specific enough and cannot be roundly used to measure the QoL of Chinese patients with GC [16]. Additionally, because of QoL strongly dependent on cultural background, foreign scales cannot be used directly after translation. Because of economic and cultural differences across regions of China, Chinese-developed instruments for patients with GC have not been widely used [17]. Therefore, it was necessary to develop the PROM for Chinese patients with GC to focus more on the related aspects of the treatment as it is perceived by patients. In addition to laboratory and imaging methods, the data from PROM can be used to improve the reliability of clinical efficacy evaluations by comprehensively measuring many aspects of patient-reported health [18]. As a result, PROs are able to provide a reference for doctors in their diagnosis and treatment practices [19]. Prior to using PRO measures in clinical practice and research, the instruments need to be cautiously developed and validated to avoid biased results that might lead to incorrect interpretations [20].

Methods
Setting
The two surveys (i.e., pre-survey and formal survey) were carried out in eight hospitals in Shanxi Province, China. These hospitals were the First Hospital of Shanxi Medical University, the Second Hospital of Shanxi Medical University, Shaxin Cancer Hospital, the 264 Hospital of Chinese People’s Liberation Army (PLA), the 17th Hospital of the Chinese Railway, the People’s Hospital of Gaoping City, the People’s Hospital of Zhezhou City, and the Fourth People’s Hospital of Linfen City.

Sample
Before collecting samples, investigators contacted related departments of target hospitals and communities to get support from hospital staff and community workers. Preparations were also made to publicize the study through posters in hospital departments and communities. The documents introducing the survey were distributed. From July 2015 to September 2015, patients diagnosed with GC were recruited. The inclusion criteria for patients with GC were as follows: patients who had been diagnosed with GC, were over 18 years old. The exclusion criteria were as follows: patients with other serious disease; patients with disturbance of consciousness; patients who were unable to understand to complete the questionnaire for any reason. We simultaneously selected healthy subjects who lived in the same communities as the patients. Healthy subjects met the following criteria: They were not suffering from other diseases of the digestive system, other malignant tumors, or mental illness; were similar in age to the patients with GC; and they volunteered to participate in the investigation.

Development and formation of GC-PROM
The GC-PROM was developed in three phases [21], and details of each phase are described below. Figure 1 presented a flowchart of three-phase development process.

Phase 1: identification of conceptual framework and items

Literature searches and patient interviews
Literature searches were carried out on network databases for keywords such as PRO measure, PRO scale, PRO instruments, and gastric cancer. Using the principles of FDA on the PROM and search results, we established a conceptual framework for GC-PROM including four domains and 13 subdomains. We conducted face-to-face interviews with 10 patients with GC. Researchers wrote down the interviewees’ original words as far as possible. After the interview, all information was sorted and an initial pool was developed.
Cognitive test and expert consultation
Other 10 hospitalized patients with GC took part in a cognitive test of the questionnaire. The group included seven men and three women, with an average age of 54 years. We also sought views from experts. In the final step, we integrated the views of experts and patients to modify the items and develop the draft version of GC-PROM.

Scale scoring
The response options of items used five-point Likert scoring scales, with scores ranging from zero to four points, including positive items (items with higher QoL) and negative items (items with lower QoL). For the convenience of calculation, positive items were recoded as the original score plus one point. The negative items were recoded as five minus the original score [22]. The higher total scores of the subdomain, the better the patients’ QoL.

Phase 2: formation of initial and final scales using two item-selection processes
During the formation process of GC-PROM, seven methods were used to select items through two item-selection processes. The first six methods were based on classical test theory (CTT). The IRT was used as the seventh method. One of IRT models (i.e., Samejima’s...
Graded Response Model) were the preferred methodology for statistically analyzing patients’ latent traits [23]. An item was considered for selection if it was retained by six or more methods. An item’s practical significance was considered before deleting in the pre-survey. If it was meaningful in fact, the item would be temporarily retained and screened in the formal survey. We finally removed this item when it was still suggested to be deleted.

**Statistical methods**

Seven methods were used to evaluate the items:

1. When the standard deviation (SD) of an item was \( \leq 1 \), the corresponding item was deleted [24].
2. We deleted items with factor loading that were low (< 0.4) or close to other factors in the exploratory factor analysis [25].
3. An item was considered for deletion when the Pearson correlation coefficient for the item and its subdomain was < 0.60 or the Pearson correlation coefficient for the item and another subdomain was > 0.50 [25].
4. An item was considered for deletion when the corrected item-total correlation was < 0.50 and the item’s deletion increased the value of Cronbach’s alpha coefficient [24].
5. Items with smaller correlation coefficients of retest reliability (< 0.6) were removed [26].
6. Each item score of patients and healthy subjects was analyzed using a \( t \)-test to distinguish the items in distinction analysis. Deletion was recommended for items with \( P \) values > 0.05 [23].
7. In the Graded Response Model, the practical values of the item parameters for deletion were as follows: item discrimination parameter (a) < 0.4 or difficulty parameter (b) \((-3, 3)\) [27].

**Phase 3: evaluation of measurement properties**

The properties of the final GC-PROM version were assessed by using data from a formal investigation.

**Evaluation of reliability**

The internal consistency of the GC-PROM was assessed by using Cronbach’s alpha coefficients of 13 subdomains. Generally, a value of more than 0.70 indicated that it had a good internal consistency [28].

**Evaluation of validity**

**Content validity** The relevant literature, subjects’ opinions, and experts were consulted in establishing the content validity, which represents how well the items captured the concept of interest [29].

**Construct validity** Confirmatory factor analysis was used to examine the structure of the GC-PROM. The standardized factor loadings for an item should be greater than 0.5 [30].

**Discriminant validity** Discriminant validity is the ability of an instrument to measure a difference between two groups. The \( t \)-test was used to compare differences between patients with GC and healthy subjects, with the significance level set at \( P < 0.05 \) [31].

**Evaluation of feasibility**

Feasibility mainly reflects the acceptability of the GC-PROM. The return and response rate of the questionnaires was rationalized with the general requirement set at \( \geq 85\% \). The questionnaire completion time was generally less than half an hour. We also took the proportion of miss data and maximum endorsement frequencies [32].

**Interpretation of PRO results: minimal clinical important difference (MCID)**

MCID was designed to solve the clinical explanation problem of a GC-PROM score change [33]. The methods used to estimate the MCID mainly include the effect size (ES), standard error of measurement (SEM), standardized response mean, and reliable change index (RCI) [34]. In this article, we used SEM and RCI to estimate the MCID.

**Results**

**Participant characteristics**

A total of 145 patients and 55 healthy subjects were included in the pre-survey. Among these subjects, 20 patients completed the questionnaire again 4 days after first completing the questionnaire. Finally, completed questionnaires were collected from 130 patients and 52 healthy subjects. All 20 retest questionnaires were recovered. In the formal survey, a total of 530 questionnaires (400 patients with GC, 130 healthy subjects) were administered. Ultimately, completed questionnaires were collected from 364 patients with GC and 112 healthy subjects. A total of 45 patients with GC were retested, and all of the retest questionnaires were recovered. We compared baseline data of two groups using \( t \)-tests for continuous variables and chi-square tests for categorical variables. The results with the significance level set at \( P < 0.05 \) showed that the baseline data from patients with GC and from healthy subjects were all comparable (Table 1).
The conceptual framework of the GC-PROM
The established conceptual framework included four domains, 13 subdomains. After the literature review and interviews with patients with GC, an initial pool of 79 items was developed. Based on the cognitive test and expert consultation, we deleted 14 items, added three items, and modified two items. Finally, conceptual framework included the scale contained 4 domains (physiological, psychological, social, and therapeutic domains), 13 subdomains (abdominal symptoms, systemic symptoms, physical state, independence, anxiety, depression, pessimism, fear, social support, social adaptation, effectiveness, satisfaction, compliance, and drug side effects), and 68 items.

Formation of the initial and final scales through two item-selection processes
Seven methods, including the SD, exploratory factor analysis, Cronbach’s alpha coefficient, retest reliability, correlation coefficient, distinction analysis, and IRT, were used to select items. Twenty-two items in the selected item pool were suggested for deletion by seven methods. Meanwhile practical meanings of 22 items were taken in account. Finally, a consensus was reached that these items should be deleted. In the second item-selection process, a formal investigation was conducted with the above reduced (i.e., 46 items) questionnaire. The items were again screened using the above seven methods and practical meanings. According to the results shown in Table 2, eight items were deleted.

Finally, the scale contained 4 domains, 13 subdomains, and 38 items (See Additional file 1). The structural framework of the final scale was shown in Table 3.

Evaluating the properties of the GC-PROM
The final GC-PROM was evaluated for validity, reliability, and feasibility using data obtained from 364 patients with GC and 112 healthy subjects.

Evaluation of reliability
Cronbach’s alpha coefficients for the four domains and 13 subdomains were between 0.700 and 0.917. As was evident in these values, the GC-PROM demonstrated a good degree of internal consistency reliability.

Table 1 Baseline data of subjects in the formal survey

| Variables          | Group       | Case     | Control | t / x²  | P   |
|--------------------|-------------|----------|---------|---------|-----|
| Home-places        | City        | 109      | 39      | 0.951   | 0.330|
|                    | countryside | 255      | 73      |         |     |
| Age (X ± s)        |             | 57.14 ± 10.08 | 55.78 ± 9.55 | 1.265  | 0.207|
| Gender             | Female      | 266      | 74      | 2.060   | 0.151|
|                    | Male        | 98       | 38      |         |     |
| Height (cm, X ± s) |             | 164.51 ± 9.21 | 164.54 ± 7.52 | −0.032 | 0.974|
| Weight (kg, X ± s) |             | 57.37 ± 11.14 | 59.17 ± 9.15 | −1.557 | 0.120|
| Marital status     | Single      | 13       | 9       | 5.321   | 0.256|
|                    | Married     | 297      | 82      |         |     |
|                    | Separated   | 19       | 7       |         |     |
|                    | Divorced    | 7        | 3       |         |     |
|                    | Widowed     | 28       | 11      |         |     |
| Occupation         | Peasant     | 174      | 45      | 2.395   | 0.880|
|                    | Worker      | 67       | 26      |         |     |
|                    | Clerk       | 33       | 11      |         |     |
|                    | Professionals| 22        | 7       |         |     |
|                    | Management  | 19       | 6       |         |     |
|                    | self-employed | 13         | 5       |         |     |
|                    | Other       | 36       | 12      |         |     |
| Monthly income     | <$150       | 196      | 55      | 0.951   | 0.813|
|                    | $150~$450 | 119      | 39      |         |     |
|                    | $450~$750  | 34       | 13      |         |     |
|                    | >$750       | 15       | 5       |         |     |
| Item   | IRT | SD | Factor analysis | CITC | Retest reliability | Correlation coefficient | P   | Outcome |
|--------|-----|----|----------------|------|--------------------|------------------------|-----|---------|
| PHD1   | 3.23| 1.141| 0.342          | 0.587| 0.923              | 0.702                  | 0.001| ✓       |
| PHD2   | 3.51| 1.179| 0.351          | 0.601| 0.887              | 0.716                  | 0.001| ✓       |
| PHD3   | 0.80| 1.060| 0.749          | 0.454| 0.882              | 0.585                  | 0.001| x       |
| PHD4   | 0.96| 1.063| 0.082          | 0.463| 0.915              | 0.593                  | 0.001| x       |
| PHD5   | 1.33| 0.923| 0.191          | 0.525| 0.791              | 0.629                  | 0.001| ✓       |
| PHD6   | 1.13| 1.066| 0.684          | 0.577| 0.839              | 0.687                  | 0.001| ✓       |
| PHD7   | 0.83| 1.181| 0.610          | 0.489| 0.927              | 0.628                  | 0.001| ✓       |
| PHD8   | 1.19| 1.001| 0.571          | 0.588| 0.882              | 0.690                  | 0.001| ✓       |
| PHD9   | 0.42| 1.093| 0.443          | 0.325| 0.928              | 0.479                  | 0.001| x       |
| PHD10  | 3.25| 0.758| 0.714          | 0.599| 0.818              | 0.817                  | 0.001| ✓       |
| PHD11  | 2.00| 0.937| 0.571          | 0.500| 0.795              | 0.814                  | 0.001| ✓       |
| PHD12  | 1.29| 0.798| 0.467          | 0.419| 0.805              | 0.725                  | 0.001| ✓       |
| PHD13  | 1.26| 1.103| 0.511          | 0.496| 0.727              | 0.769                  | 0.001| ✓       |
| PHD14  | 9.30| 1.019| 0.437          | 0.772| 0.846              | 0.901                  | 0.001| ✓       |
| PHD15  | 3.46| 1.102| 0.330          | 0.700| 0.826              | 0.876                  | 0.001| ✓       |
| PHD16  | 5.25| 1.129| 0.814          | 0.799| 0.905              | 0.946                  | 0.001| ✓       |
| PHD17  | 4.32| 1.176| 0.780          | 0.799| 0.955              | 0.951                  | 0.001| ✓       |
| PSD1   | 3.32| 1.124| 0.830          | 0.691| 0.809              | 0.875                  | 0.001| ✓       |
| PSD2   | 3.77| 1.195| 0.869          | 0.713| 0.844              | 0.894                  | 0.003| ✓       |
| PSD3   | 1.18| 1.800| 0.754          | 0.718| 0.865              | 0.817                  | 0.005| x       |
| PSD4   | 2.41| 1.031| 0.788          | 0.683| 0.866              | 0.805                  | 0.001| ✓       |
| PSD5   | 3.33| 1.091| 0.799          | 0.757| 0.914              | 0.858                  | 0.002| ✓       |
| PSD6   | 3.41| 1.101| 0.757          | 0.744| 0.921              | 0.851                  | 0.001| ✓       |
| PSD7   | 2.88| 1.044| 0.908          | 0.761| 0.905              | 0.905                  | 0.001| ✓       |
| PSD8   | 1.21| 1.022| 0.544          | 0.485| 0.886              | 0.663                  | 0.001| ✓       |
| PSD9   | 2.90| 1.085| 0.832          | 0.755| 0.834              | 0.887                  | 0.001| ✓       |
| PSD10  | 3.52| 1.149| 0.849          | 0.781| 0.822              | 0.906                  | 0.001| ✓       |
| PSD11  | 5.12| 1.145| 0.835          | 0.814| 0.743              | 0.921                  | 0.001| ✓       |
| SOD1   | 4.27| 0.827| 0.883          | 0.740| 0.860              | 0.868                  | 0.006| ✓       |
| SOD2   | 5.00| 1.044| 0.908          | 0.761| 0.905              | 0.905                  | 0.001| ✓       |
| SOD3   | 1.86| 1.079| 0.813          | 0.622| 0.835              | 0.844                  | 0.001| ✓       |
| SOD4   | 1.01| 0.948| 0.522          | 0.399| 0.881              | 0.575                  | 0.001| x       |
| SOD5   | 1.41| 1.117| 0.717          | 0.569| 0.838              | 0.730                  | 0.001| ✓       |
| SOD6   | 6.85| 1.126| 0.926          | 0.842| 0.737              | 0.909                  | 0.001| ✓       |
| SOD7   | 5.99| 1.111| 0.918          | 0.834| 0.711              | 0.904                  | 0.001| ✓       |
| SOD8   | 2.52| 1.176| 0.813          | 0.662| 0.764              | 0.801                  | 0.001| ✓       |
| THD1   | 3.63| 1.031| 0.863          | 0.829| 0.776              | 0.926                  | 0.001| ✓       |
| THD2   | 7.16| 1.098| 0.780          | 0.746| 0.696              | 0.893                  | 0.001| ✓       |
| THD3   | 2.78| 1.20 | 0.657          | 0.544| 0.880              | 0.885                  | 0.001| ✓       |
| THD4   | 2.04| 0.854| 0.601          | 0.544| 0.736              | 0.872                  | 0.001| ✓       |
| THD5   | 2.85| 0.812| 0.601          | 0.544| 0.736              | 0.872                  | 0.001| ✓       |
| THD6   | 3.61| 0.888| 0.868          | 0.780| 0.811              | 0.908                  | 0.001| ✓       |
| THD7   | 13.24| 0.782| 0.936          | 0.893| 0.826              | 0.951                  | 0.001| ✓       |
Evaluation of validity

Content validity To ensure that all the items appropriate, we assessed content validity by referring to the relevant previous literature. Face-to-face interviews were conducted with patients with GC to identify potential items. Meanwhile, we also consulted with experts for item refinement.

Construct validity The indexes of fit for four domains (Root Mean Square Residual: 0.048–0.079; Normed Fit Index: 0.91–0.97; Bentler Comparative Fit Index: 0.91–0.98, incremental fit index: 0.91–0.98.) met the defined criteria, which were strongly suggested by the high factor loading. The results of confirmatory factor analysis appear in Table 4. The standardized factor loadings of 13 subdomains were greater than 0.5. Therefore, the construct validity was deemed satisfactory.

Discriminant validity The results of discriminant validity are shown in Table 5. The results of discriminant validity (P values < 0.05) suggested that the GC-PROM was an appropriate instrument to distinguish between patients and healthy subjects.

Table 3 Scale structure of the final GC-PROM

| Domains          | Subdomains          | Item   |
|------------------|---------------------|--------|
| Physical domain  | Abdominal symptoms  | 1-, 2-, 3-, 4-, 5- |
|                  | Systemic symptoms   | 6-, 7- |
|                  | Physical state      | 8-, 9-, 10- |
|                  | Independence        | 11+, 12+ |
| Psychological domain | Anxiety       | 1-, 2- |
|                  | Depressed           | 3-, 4-, 5-, 6- |
|                  | Pessimism           | 7-, 8-, 9- |
| Social domain    | Social support      | 1+, 2+, 3+ |
|                  | Social adaptation   | 4+, 5+, 6+, 7+ |
| Therapeutic domain | Effectiveness   | 1+, 2+, 3+ |
|                  | Satisfaction        | 4+, 5+ |
|                  | Compliance          | 6+, 7+, 8+ |
|                  | Drug side effects   | 9-, 10- |

Negative items were denoted by “-”. Positive items were denoted by “+”.

Evaluation of feasibility

In this formal survey, the return and response rate of questionnaires were 93.40 and 96.16%, respectively. The average completing time was less than half an hour. No major floor or ceiling effects were found. The maximum proportion of participants who endorsed a single category for each item was less than 80%. Only 3.84% of the responses to individual items were missing. We tested the missing questionnaire data using Little’s Missing Completely at Random Test. The test showed that the data were missing at random, and we filled them in using the Expectation-Maximization Algorithm.

MCID

From statistical results of Table MCID, the value of the MCID was greater when determined using the RCI than when it was determined using the SEM. Therefore, the value of MCID determined using the RCI was chosen as the final judgment. We finally identified the minimum clinical values of 4.14, 3.41, 3.37, and 3.28 in the physiological, psychological, social, and therapeutic domains, respectively.

Discussion

There is increasing recognition that PROs are important in the estimation of the burden of long-term survival among patients with GC. In this environment, it is essential to get more acquainted with information regarding patients’ QoL [3]. Therefore, the present study developed a reliable and valid patient-reported scale for patients with GC in China. Using the currently available PRO instruments as a starting point, we developed the GC-PROM to assess the QoL of patients with GC. The GC-PROM comprises four domains, 13 subdomains, and 38 items. The results of our study indicated that the GC-PROM is a valid instrument for measuring quality of life among patients with GC. The application of PROs in the evaluation of curative effects could make clinicians more aware of the patient’s situation and provide a reference for diagnosis and treatment [7].

Quality of life research conducted in China has historically involved the use of questionnaires that have been translated from another language. As a result some of the items have been inconsistent with some habits...
Table 4 Results of the CFA

| Subdomains         | Item  | Nonstandard Factor Loading | Standard Factor Loading | standard error | t    |
|--------------------|-------|----------------------------|-------------------------|----------------|------|
| Abdominal symptoms | PHD1  | 1.00                       | 0.87                    | 0.05           | 19.57|
|                    | PHD2  | 1.01                       | 0.86                    | 0.05           | 19.04|
| Systemic symptoms  | PHD3  | 0.61                       | 0.50                    | 0.06           | 7.77 |
|                    | PHD4  | 0.60                       | 0.50                    | 0.06           | 7.77 |
|                    | PHD5  | 0.50                       | 0.50                    | 0.05           | 9.70 |
| Physical state     | PHD6  | 0.56                       | 0.74                    | 0.04           | 13.06|
|                    | PHD7  | 0.68                       | 0.72                    | 0.05           | 12.75|
| Independence       | PHD8  | 0.63                       | 0.57                    | 0.06           | 11.40|
|                    | PHD9  | 0.92                       | 0.91                    | 0.04           | 20.671|
|                    | PHD10 | 0.95                       | 0.86                    | 0.05           | 19.261|
| Anxiety            | PSD1  | 0.96                       | 0.85                    | 0.05           | 17.681|
|                    | PSD2  | 1.02                       | 0.86                    | 0.06           | 17.791|
|                    | PSD3  | 0.78                       | 0.75                    | 0.05           | 16.041|
|                    | PSD4  | 0.92                       | 0.84                    | 0.05           | 18.861|
|                    | PSD5  | 0.89                       | 0.81                    | 0.05           | 17.781|
|                    | PSD6  | 0.54                       | 0.51                    | 0.05           | 10.231|
| Pessimism          | PSD7  | 0.88                       | 0.81                    | 0.05           | 18.181|
|                    | PSD8  | 0.97                       | 0.84                    | 0.05           | 19.171|
|                    | PSD15 | 1.03                       | 0.90                    | 0.05           | 21.271|
| Social support     | SOD1  | 0.70                       | 0.85                    | 0.04           | 18.211|
|                    | SOD2  | 0.94                       | 0.90                    | 0.05           | 19.641|
|                    | SOD3  | 0.72                       | 0.66                    | 0.05           | 13.541|
| Social adaptation  | SOD4  | 0.68                       | 0.61                    | 0.05           | 12.431|
|                    | SOD5  | 1.05                       | 0.94                    | 0.05           | 22.911|
|                    | SOD6  | 1.02                       | 0.92                    | 0.05           | 22.261|
|                    | SOD7  | 0.89                       | 0.76                    | 0.05           | 16.741|
| Effectiveness      | THD1  | 0.83                       | 0.85                    | 0.04           | 19.391|
|                    | THD2  | 0.93                       | 0.90                    | 0.04           | 21.181|
|                    | THD3  | 0.91                       | 0.83                    | 0.05           | 18.611|
| Satisfaction       | THD4  | 0.72                       | 0.84                    | 0.05           | 15.161|
|                    | THD5  | 0.53                       | 0.65                    | 0.04           | 11.971|
| Compliance         | THD6  | 0.73                       | 0.82                    | 0.04           | 18.701|
|                    | THD7  | 0.75                       | 0.96                    | 0.03           | 24.321|
|                    | THD8  | 0.74                       | 0.90                    | 0.03           | 21.601|
| Drug side effects  | THD9  | 0.77                       | 0.79                    | 0.06           | 12.271|
|                    | THD10 | 0.74                       | 0.72                    | 0.06           | 11.521|

PHD: physiological domain. PSD: psychological domain. SOD: social domains. THD: therapeutic domain
clinical trials [9]. These subdomains (i.e., effectiveness, compliance, drug side effects) can provide related information about the effects of the targeted drug on patients’ quality of life and identify the acceptance of new drug among patients. Researchers can promote clinical therapeutic drug development and select an optimal therapy based on information and data gained. In the social field, family relationship is emphasized to recognize the importance of family support during the recovery of patients.

Exploratory factor analysis was carried out in the four domains based on one-dimensional assumption of the IRT [27]. The Kaiser-Meyer-Olkin values in four domains were 0.822, 0.875, 0.761, and 0.774 in the first item-selection process. The \( P \) value of Bartlett’s spherical test was < 0.001, indicating that the data were suitable for factor analysis. Four factors, three factors, two factors, and four factors with characteristic root greater than 1 were extracted from physical, psychological, social and therapeutic domains respectively. The factor analysis also showed that each factor (i.e., subdomain) had the unidimensionality. The method of GRM ran on the items of each subdomain.

There were many methods used in the selecting items. A variety of methods were used to ensure the quality of the selection and to make selected items more representative, independent, and sensitive. Previous research mostly used the method of CTT for item selection. Recently, IRT has gradually gained popularity for selecting items [23]. GRM is one of the most commonly used IRT models, and is suitable for Likert-type scales. The GRM method was used as a criterion for selecting items in our study. The significance of IRT is that it can guide item selection and test construction. The information function of IRT can be used to describe items’ measurement validity, which can be used as direction for the formation and modification of these items [24]. Therefore, the present study used IRT in the process of creating the GC-PROM.

To obtain reliable and accurate parameter estimates, some scholars have suggested that the sample size should be 5 to 10 times the number of observed variables in a factor analysis [20]. Most previous work that has applied item response theory (IRT) has not specified the sample size [35]. We conducted a pre-survey among a small sample (145 patients with GC and 55 healthy subjects) using a 68-item questionnaire. The purpose of this pre-survey was to ask patients how they felt about the GC-PROM items. This avoided ambiguity in understanding and reduced omission of important information. Patients were also able to point out the shortcomings of the scale in the pre-survey. For the formal survey, a larger sample (400 patients with GC and 130 healthy subjects) responded to a questionnaire with a reduced number of items (46 items) to improve the rationality of the GC-PROM.

In the development stage of the GC-PROM, we used healthy subjects as a control group to evaluate discriminant validity. The scores of the healthy subjects on the 13 subdomains could be used as baseline values. In the practical application of the GC-PROM, we will evaluate the instrument’s discriminant validity using patients with gastrointestinal diseases and non-GC patients as controls in the future. Concurrent validity was not evaluated as part of the validation stage of the GC-PROM because the simultaneous use of other previous scales in the actual investigation phase may result in estimation bias. And conducting multiple questionnaires will cause some burden to patients with GC, which may increase patient’s boredom and survey cost. Therefore, this study

| Table 5 | Scores comparisons between healthy subjects and patients with GC (X ± s) |
|---------|------------------|------------------|------------------|------------------|
| Subdomains | Patients with GC | healthy subjects | Cohen’s d | t / r | \( P \) |
| Abdominal symptoms | 17.09 ± 4.06 | 23.41 ± 1.33 | 2.09 | 16.210 | < 0.001 |
| Systemic symptoms | 8.48 ± 1.49 | 9.37 ± 0.83 | 0.73 | 6.077 | < 0.001 |
| Physical state | 9.50 ± 2.73 | 14.24 ± 1.05 | 2.29 | 17.942 | < 0.001 |
| Independence | 5.82 ± 2.19 | 9.04 ± 1.24 | 1.81 | 14.875 | < 0.001 |
| Anxiety | 5.65 ± 2.16 | 9.46 ± 0.92 | 2.30 | 18.189 | < 0.001 |
| Depressed | 14.39 ± 3.42 | 19.39 ± 0.65 | 2.03 | 15.371 | < 0.001 |
| Pessimism | 10.97 ± 3.06 | 14.94 ± 0.31 | 1.83 | 13.692 | < 0.001 |
| Social support | 11.57 ± 2.57 | 14.03 ± 1.18 | 1.23 | 9.778 | < 0.001 |
| Social adaptation | 13.24 ± 3.86 | 19.29 ± 0.92 | 2.16 | 16.424 | < 0.001 |
| Effectiveness | 10.26 ± 2.82 | 13.87 ± 1.20 | 1.67 | 13.178 | < 0.001 |
| Satisfaction | 7.12 ± 1.46 | 8.20 ± 1.06 | 0.85 | 7.228 | < 0.001 |
| Compliance | 12.34 ± 2.31 | 13.76 ± 1.42 | 0.74 | 6.162 | < 0.001 |
| Drug side effects | 6.46 ± 1.77 | 9.15 ± 0.80 | 1.96 | 15.636 | < 0.001 |
also did not include specific comparison results between this scale and other conventional questionnaires such as EORTC QLQ-STO52 or FACT-Ga. We could not compare the validity between the newly developed questionnaire (GC-PROM) and conventional ones. In the subsequent questionnaire survey, multiple scales of gastric cancer (e.g., GC-PROM, EORTC QLQ-STO52, and FACT-Ga) will be used to evaluate the QoL of patients with GC and compare the concurrent validity. We used a distribution-based method to determine the value of the MCID. In the formal investigation, the repeated-measures sample size was relatively small. These conditions were not very suitable for using the anchor-based method. In future studies, we will further standardize the sample size and the time interval for repeated measurements. Shanxi is a Mandarin-speaking province in northern China. Therefore, in the actual survey, the GC-PROM was in Mandarin, which is the standardized language commonly used in China. This approach ensured that the scale could be used in most areas of China, where Mandarin is used. However, in a few areas of southern China, such as Guangdong and Shenzhen, the most common language is Cantonese. For use in these areas, the newly developed GC-PROM would require further adjustment and verification.

Conclusions
This project essentially completed the development and validation of the GC-PROM according to the PRO production process stipulated by the United States Food and Drug Administration. GC-PROM can be considered an effective clinical evaluation instrument for patients with GC.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12885-020-6518-z.

Additional file 1. Final version of GC-PROM. After two item-selection process based on classical test theory and item response theory, the final GC-PROM consisted of 38 items. It described which items were included in the final scale.

Abbreviations
CTT: Classical test theory; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer quality of life questionnaire-core questionnaire; EORTC QLQ-STO52: European Organization for Research and Treatment of Cancer quality of life questionnaire-stomach module; FACT-Ga: Functional Assessment of Cancer Therapy-gastric; GC: Gastric cancer; GC-PROM: patient-reported outcomes measure for patients with gastric cancer; IRT: Item response theory; MCID: Minimal clinically important difference; PRO(s): patient-reported outcome(s); QLICP-ST: quality of life instruments for gastrointestinal cancer patients-stomach cancer; QoL: quality of life; RCI: Reliable change index; SEM: Standard error of measurement

Acknowledgements
We are grateful to the eight hospitals in Shanxi Province that participated in this study.

Authors' contributions
All authors participated in the study design. XH and FZ were responsible for collecting the data and drafting the article. YH and YL participated in the data analysis. JL and YZ proposed the original concept for this study, supervised the data analysis, and revised the paper. All authors read and approved the final manuscript.

Funding
This study was funded by the National Natural Science Foundation of China (Grant No. 81273180) and Key research and development project of Shanxi Province (Grant No.201603D321101). The funder of two funds is the last corresponding author. Both funding bodies supported study design and data collection.

Availability of data and materials
Please contact the corresponding author for the study data, which will be granted upon reasonable request.

Ethics approval and consent to participate
The research protocol (No.2013099) and questionnaire received approval from the Ethics Committee of Shanxi Medical University. We received written consent from all participants.

Consent for publication
Not Applicable.

Competing interests
Xiaojian Hu, Fen Zhao, Hongmei Yu, Yanhong Luo, Jinchun Liu, and Yanbo Zhang declare that they have no conflict of interest.

Author details
1Department of Health Statistics, School of Public Health, Shanxi Medical University, 56 South Xinhua Road, Taiyuan 030001, Shanxi Province, China. 2Department of Internal Medicine, Shanxi Provincial Peoples Hospital, 29 Twin Towers Temple Street, Taiyuan 030012, Shanxi Province, China. 3Department of Internal Medicine, First Hospital of Shanxi Medical University, 85 South Jiefang Road, Taiyuan 030001, Shanxi Province, China.

Received: 30 August 2019 Accepted: 6 January 2020

Published online: 16 January 2020

References
1. Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastroenterol. 2012;4(7):156.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5–29.
3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.
4. Weimann L, Liyun H, Baoyan L, Mingjie Z. Application of patient-reported outcome in Cancer study. World Sci Technol. 2010;12(2):177–80.
5. Paschali AA, Hadjulis M, Papadimitriou A, Karademas EC. Patient and physician reports of the information provided about illness and treatment: what matters for patients’ adaptation to cancer during treatment? Psycho-Oncology. 2015;24(8):901–9.
6. Flores LT, Bennett AV, Law EB, Haji C, Griffith MP, Goodman KA. Patient-reported outcomes vs. clinician symptom reporting during chemoradiation for rectal cancer. Gastrointest Cancer Res. 2012;5(4):119.
7. Howell D, Mollov S, Wilkinson K, Green E, Orchard K, Wang K, et al. Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol. 2015;26(9):1846–58.
8. Spiegel BM. Patient-reported outcomes in gastroenterology: clinical and research applications. J Neurogastroenterol Motil. 2013;19(2):137.
9. of Health UD, for Drug HSFC. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006:4:79.
10. Rausel S, Mangano A, Galli F, Rovera F, Boni L, Dionigi G, et al. Quality of life after gastrectomy for cancer evaluated via the EORTC QLQ-C30 and QLQ-ST022 questionnaires: surgical considerations from the analysis of 103 patients. Int J Surg. 2013;11:5104–59.
11. Garland SN, Pelletier G, Lawe A, Biagioni BJ, Easaw J, Eliaziw M, et al. Prospective evaluation of the reliability, validity, and minimally important difference of the functional assessment of cancer therapy-gastric (FACT-Ga) quality-of-life instrument. Cancer. 2011;117(6):1302–12.

12. Chen J-G, Song X-M. An evaluation on incident cases of liver Cancer in China [J]. Bull Chin Cancer. 2005;1:28–31.

13. Dobrozsi S, Panepinto J. Patient-reported outcomes in clinical practice. ASH Educ Program Book. 2015;2015(1):501–6.

14. Meng Q, Wan C-H, Luo J-H, Tang X-L, Li Y-F, Cun Y-L, et al. Development of the system of quality of life instruments for cancer patients. Chin J Cancer. 2008;27(11):604–8.

15. Yang Z, Lu J-G, You S-F. Development of the quality of life assessment system for cancer based on traditional Chinese medicine-lung cancer (QLASTCM-LU)[J]. Mod Prev Med. 2011;18.

16. Kaptein AA, Moita S, Sakamoto J. Quality of life in gastric cancer. World J Gastroenterol. WJG. 2005;11(21):3189.

17. Yan H, Sellick K. Symptoms, psychological distress, social support, and quality of life of Chinese patients newly diagnosed with gastrointestinal cancer. Cancer Nurs. 2004;27(5):399–99.

18. Bennett AV, Jensen RE, Basch E. Electronic patient-reported outcome systems in oncology clinical practice. CA Cancer J Clin. 2012;62(5):336–47.

19. Brédart A, Marel A, Abetz-Webb L, Lasch K, Acquadro C. Interviewing to develop patient-reported outcome (PRO) measures for clinical research: eliciting patients’ experience. Health Qual Life Outcomes. 2014;12(1):15.

20. Anthoine E, Morel L, Regnault A, Sébille V, Hardouin J-B. Sample size used to validate a scale: a review of publications on newly-developed patient reported outcomes measures. Health Qual Life Outcomes. 2014;12(1):2.

21. Bradley C. Feedback on the FDA’s February 2006 draft guidance on patient reported outcome (PRO) measures from a developer of PRO measures. Health Qual Life Outcomes. 2006;4(1):28.

22. Lipscomb J, Goyat CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J Clin. 2007;57(5):278–308.

23. Cappelleri JC, Lundy JJ, Hays RD. Overview of classical test theory and item response theory for the quantitative assessment of items in developing patient-reported outcomes measures. Clin Ther. 2014;36(5):648–62.

24. Lai J-S, Cook K, Stone A, Beaumont J, Cella D. Classical test theory and item response theory/Rasch model to assess differences between patient-reported fatigue using 7-day and 4-week recall periods. J Clin Epidemiol. 2006;59(9):911–7.

25. Meads DM, Bentall RP. Rasch analysis and item reduction of the hypomanic personality scale. Personal Individ Differ. 2008;44(8):1772–83.

26. Johns MW. Reliability and factor analysis of the Epworth sleepiness scale. Sleep. 1992;15(4):376–81.

27. Nguyen TH, Han H-R, Kim MT, Chan KS. An introduction to item response theory for quantitative assessment of items in developing patient-reported outcomes measures. Clin Ther. 2014;36(5):648–62.

28. Nanjundeswaran C, Jacobson BH, Gartner-Schmidt J, Abbott KV. Vocal fatigue index (VFI): development and validation. J Voice. 2015;29(4):433–40.

29. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of Cancer therapy scale: development and validation of the general measure. J Clinc Oncol. 1993;11(3):570–9.

30. Maydeu-Olivares A, Fairchild AJ, Hall AG. Goodness of fit in item factor analysis: effect of the number of response alternatives. Struct Equ Model Multidiscip J. 2017;24(4):498–505.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.